2,6-methano-2H-quinolizin derivative as 5-HT.sub.3 -receptor antagonist
AssigneeMerrell Pharmaceuticals Inc.
InventorMaurice W. Gittos
Life of this patent
Estimating the term…
Abstract
This invention relates to 5-chloro-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acid-octahydro-3-hydroxy-2,6-methano-2H-quinolizin-8-yl ester (I), a novel 5-HT.sub.3 -receptor antagonist, its method of preparation, and to its end-use application in the treatment or radio- and chemo-therapeutically-induced nausea and vomiting, in the treatment or pain associated with migraine, in the treatment of cognitive disorders, in treating hallucinatory endogenous psychoses or the type manifested in patients suffering from schizophrenia and mania, for irritable bowel syndrome, and to combat drug abuse.
Claims3
A compound of the formula ##STR2## its tautomers, stereo- and geometrical isomers, and mixtures thereof, or the pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.